Tumor News and Research

RSS

Y chromosome loss linked to poor cancer outcomes

When cancer cells in male patients and immune cells in their tumors both lose the Y chromosome, those patients tend to experience poorer outcomes than patients without Y chromosome loss, according to new findings from Cedars-Sinai investigators.

4 Jun 2025

LabGenius Therapeutics appoints Dr. Angus Sinclair as Chief Scientific Officer

LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize complex therapeutic antibodies, including those with multispecific designs.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Early camizestrant therapy keeps advanced breast cancer in check

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced breast cancer. The proactive, biomarker-guided approach allows earlier intervention and may redefine standard care.

3 Jun 2025

Myeloid cells shape tumor microenvironments and influence cancer progression

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic resistance.

3 Jun 2025

How soy and gut microbes alter cancer treatment results

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes.

2 Jun 2025

THP regimen achieves high response rates in HER2 positive breast cancer patients

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

2 Jun 2025

Canine DNA study uncovers new genes linked to gastric cancer

Dogs share our homes, our habits and sometimes, our diseases. Gastric cancer is rare in dogs, but when it does strike, it closely resembles gastric cancer in humans: subtle clinical signs, comparable tumor subtypes, late-stage diagnosis and poor outcomes.

2 Jun 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

Terbium therapy shows promise in fighting lymphoma

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI in collaboration with Inselspital - Bern University Hospital.

2 Jun 2025

Researchers identify gene driving aggressive prostate cancer

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form.

2 Jun 2025

Genome doubling identified as common event in metastatic cancer evolution

When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity.

2 Jun 2025

New combination treatment offers hope for immune checkpoint blockade resistant skin cancers

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.

2 Jun 2025

Treatment switching guided by liquid biopsy results improves outcomes in advanced breast cancer

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

1 Jun 2025

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

1 Jun 2025

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Gene expression study reveals clues to asbestos-linked mesothelioma

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer.

31 May 2025

Light-powered phagocytic macrophage microrobot combines immune functions with robotic controllability

Macrophages and other immune cells are the natural frontline immune warriors of our body, defending the body against invading pathogens and cancer cells.

31 May 2025

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.

30 May 2025